Page 1

By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them. You can change your Cookie Settings at any time but parts of our site will not function correctly without them. BS APPS

JUST IN

BS PRODUCTS

SIGN IN

BS E-PAPER BS LEARNING

Investors want higher price in Fortis open offer; IHH unlikely to

Search

SUBSCRIBE

News

You are here: Home » Companies » News

Morepen labs gets USFDA nod for cholesterol, asthma bulk drug mfg units Atorvastatin and Montelukast have shown great growth potential during last 5 years, with a CAGR of 25% and 17% respectively ANI | New Delhi [India] Last Updated at July 30, 2018 15:02 IST

ALSO READ

Morepen Laboratories Ltd. has received US FDA


Morepen Laboratories surges 14% on USFDA approval for Baddi facility Dr Reddy's recalls 80k bottles of Atorvastatin from US over quality issue Ipca on recovery path over FDA clearance, growth in Africa tender business Dr Reddy's gets 5 observations from US FDA for API unit at Hyderabad Dr Reddy's gains 4% as API Srikakulam plant gets USFDA clearance

(United States Food and Drug Administration) approvals for both its bulk drugs manufacturing facilities situated in Himachal Pradesh. While the Baddi facility has got US FDA approval for the manufacture of bulk drug "Atorvastatin Calcium", a Cholesterol reducing drug, the Masulkhana facility has recently got the nod for manufacturing an antiasthma bulk drug "Montelukast Sodium" for export to the US market. It is significant to note here that the US market size for these two bulk drugs viz. Atorvastatin Calcium and Montelukast Sodium is approximately Rs. 5,000 crore and Rs. 2,000 crore respectively. The two APIs collectively contributes around Rs. 150 crore annual revenue to the company's top line and constitutes 44 per cent of the company's total API business.

The main API facility situated at Baddi (Himachal Pradesh) houses multiple plants for manufacture of different drugs, including Atorvastatin, and is spread across an area of around 50 acres. The Masulkhana facility of Morepen Labs got its first USFDAapproval for the manufacture of 'Loratadine' in the year 1999, followed by another USFDA approval for 'Desloratadine' in the year 2011. "Montelukast" is the third API approved out of this plant. "With this development in place, the company is set to expand its foothold in the combined Rs. 7,000 crore US market for Atorvastatin and Montelukast. The two APIs will also strengthen company's existing APIs portfolio comprising Loratadine and Desloratadine in the US market," said chairman and MD, Morepen Laboratories Ltd., Sushil Suri. Morepen Labs got an initial US FDA clearance for Montelukast Sodium in December 2017, based upon approval of customer's ANDA which triggered an inspection of its Masulkhana facility in 2018. The facility had gone for regular inspection for all the three products manufactured therein viz. Loratadine, Desloratadine (already approved) and Montelukast (new approval). Similarly, the Baddi plant was also inspected by US FDA for the first time, triggered by a US customer for supply of Atorvastatin to the US markets. The inspection got concluded this month itself. This plant mainly manufactures Atorvastatin amongst other APIs. Following this inspection, both the facilities of Masulkhana and Baddi have been approved without any deficiency and US FDA has not given any adverse remark/ observation (i.e. no Form 483 has been issued), besides a complete approval of the two plants' quality parameters has been accorded. "With the help of our experienced and dedicated team, we are fully committed to service the regulated markets and fulfil the compliance requirements for US, European and other global customers. We are continuously working on scaling up our R&D efforts to become a niche player in the global API markets. R&D team of the company is working relentlessly for churning out new technologies and innovative processes towards cost reduction and also towards process simplification," added Suri. Atorvastatin and Montelukast have shown great growth potential during last 5 years, with a CAGR of 25% and 17% respectively. The company expects decent incremental revenues with more US business coming to company's kitty in the coming years. The Masulkhana plant was also inspected and approved by the Therapeutic Goods Agency (TGA), Australia in 2015; minor improvements were made in keeping with the TGA requirements. In addition, the plant has received an EU-GMP certification following an inspection by the Slovenian drug regulatory authorities in 2013. This apart, Morepen also supplies the APIs for Canada and the European Union since 1999, and intermediates for Loratadine for the Japanese market. Its application for marketing of API (known as DMF or Drug Master File) is under consideration of the Japanese authority. The company has a very strong regulatory department and has filed 45 Drug Master Files for all APIs with international documentation and validation data. It has been granted six Certificate of Suitability (COS) applicable in 28 European countries. First Published: Mon, July 30 2018. 14:59 IST READ MORE ON

MOREPEN

MOREPEN LABORATORIES LTD

US FDA

API BUSINESS


HIMACHAL

MASULKHANA

ATORVASTATIN CALCIUM

COMPANIES

PREVIOUS STORY

NEWS

NEXT STORY

Oracle accused of defrauding

Counterfeit products hit direct

Adani Carmichael project test

investors, fabricating on cloud

selling industry in India: KPMG-

case for future Indian investment:

sales growth

Ficci study

Aus report

RECOMMENDED FOR YOU

Advertisements

Business Standard book for IBPS: 3000 GK Questions: GST, Budget 2017, Demonetisation

You Might Also Like

Chidambaram walks out of party meet in TN after scuffle among workers

Cryptokidnapping Gujaratstyle, or how to lose $3 bn of bitcoin in India

Five money-making Why Chinese repression in instruments in a rising interest- Xinjiang could be belt and rate environment road's stumbling block

Extended trading hours from October 1, says NSE CEO Vikram Limaye

After meeting employees, Jet Airways withdraws 25% salary cut proposal

Promoted Stories

France AC Companies Angry At This New Tiny Device handytechgadgets.com

Air Conditioning Now Finally Affordable In France Thanks To AirCool. Read More...

Calculez l’âge de votre cerveau en 5 minutes Testez votre cerveau

AirCool 24

350.000 français n'ont plus mal au dos grâce à ça. Les Maux de Dos

Le déclic pour perdre enfin vos kilos en trop (faites ceci tous les jours)

Un repas complet et équilibré concentré dans cette barre Feed. Smart Food

Cell'innov Recommended by


Companies Overview

GO

LATEST NEWS IN THIS SECTION ALL

Investors want higher price in Fortis open offer; IHH unlikely to oblige

IT service deal wins up but incremental revenue remains area of concern

Distributor body challenges Morningstar to public debate on expense ratios

Oracle accused of defrauding investors, fabricating on cloud sales growth

Advertisement

More >

MOST POPULAR READ

SHARE

COMMENTED

Microsoft CEO Satya Nadella sells $36 million in stock in biggest sale TCS may make cognitive automation software ignio as a standalone firm Indian Oil posts 50% jump in Q1 net at Rs 70.9 bn; income up at Rs 1.52 trn

No more free insurance for

FINANCIAL X-RAY


No more free insurance for train travel, opt out or pay up: Railways

SBI posts Rs 49 bn loss in Q1: One-time provision hit disappoints investors

Advertisement

With good steel demand, SAIL's profitability improvement continues Page Industries profits driven by cost management, stock gains over 7% More >

Business Standard 356,721 likes

Like Page

Contact Us

Be the first of your friends to like this

Business Standard 7 minutes ago

Researchers in Australia have come out with a 500-page report on how to tap India's economy and at the same time cut overdependence on China

MORE ON MARKETS: QUICK LINKS

BROWSE STOCK COMPANIES

STOCK MARKET LIVE

A

STOCK MARKET NEWS

B P

PORTFOLIO

DERIVATIVES

1

COMMODITY MARKET

MUTUAL FUNDS

UPCOMING IPO

GOLD PRICE

2

D R

3

E

S 4

F

T 5

G

U 6

H

V 7

I

W 8

J X

K

L

Y

M

N

O

M

N

O

Z

9

BROWSE MUTUAL FUNDS A

B P

PERSONAL FINANCE

C

Q

C

Q

D R

E

S

F

T

U

G V

H W

I

J X

K

L

Y

Z

SENSEX

INDEX STOCKS Adani Ports GAIL (India)

Asian Paints Grasim Inds

Axis Bank HDFC

Hindustan Petroleum Corporation Ltd Kotak Mah. Bank Sun Pharma. Inds.

Larsen & Toubro Tata Motors

UltraTech Cement Ltd

TRENDING ON BS

UPL Ltd

BPCL

Bajaj Auto

HCL Technologies ICICI Bank Lupin

Bajaj Finance Ltd Cipla

HDFC Bank

Bajaj Finserv

M&M

Maruri Suzuki

Hero Motocorp

Tata Steel

Vedanta

Yes Bank

Wipro

#BSWeekend

#BSTech

NTPC

TCS

Hind. Unilever

ONGC

Power Grid Corpn

Tech Mahindra

Titan Company

#BSSpecial

Bharti Infra.

Eicher Motors

Indian Oil Corporation Ltd.

Zee Entertainment #GST

Bharti Airtel

Dr Reddy's Labs

Indiabulls Housing Finance

Tata Motors-DVR

#Markets

Coal India

Hindalco Inds. IndusInd Bank Infosys

ITC

Reliance Inds. St Bk of India


FROM BS WEBSITE Home Companies Markets Opinion Politics Technology Specials Personal Finance Latest News Today's Paper RBI Policy General News General Videos General Photo Gallery Events Authors Education

ABOUT US About Us Code of Conduct Terms & Conditions Cookie Policy Disclaimer Investor Communication List of our GST registration number

SUPPORT & CONTACT Partner with Us Careers Advertise with Us Contact Us Feedback Browser Support Sitemap

SUBSCRIBE E-Paper BS Magazines Portfolio Tracker

BS PRODUCTS Smart Investor BS Hindi BS Motoring BS Books B2B Connect iPhone iPad android wap BS Banking Round Table 2017 BS Fund Cafe 2017 Budget Insight Out ELECTION Karnataka Election 2018

SPORTS IPL 2018


FIFA World Cup 2018

CONNECT WITH BS Facebook Google+ Linkedin Twitter Youtube RSS

morepen Sushil suri cbi  
morepen Sushil suri cbi  
Advertisement